サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1451738

ファブリー病市場レポート：タイプ別、診断・治療別、エンドユーザー別、地域別、2024-2032

Fabry Disease Market Report by Type (Type 1, Type 2, and Others), Diagnosis and Treatment (Diagnosis, Treatment), End User (Hospitals, Homecare, Specialty Clinics, and Others), and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 148 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.97円
ファブリー病市場レポート：タイプ別、診断・治療別、エンドユーザー別、地域別、2024-2032
出版日: 2024年03月02日
発行: IMARC
ページ情報: 英文 148 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のファブリー病市場規模は2023年に20億米ドルに達しました。今後、IMARC Groupは、2024年から2032年にかけて6.34%の成長率（CAGR）を示し、市場は2032年までに36億米ドルに達すると予測しています。ファブリー病に罹患する患者数の増加と、遺伝子治療や酵素補充療法などの効果的な新規治療に対するニーズの高まりが、市場を牽引する主な要因の一つです。

ファブリー病（αガラクトシダーゼA欠損症）は、重度のx連鎖性リソソーム遺伝性疾患であり、油、脂肪酸、ワックスなど様々な脂質貯蔵成分や脂肪様成分の代謝に必要な酵素の欠乏によって引き起こされます。診断されないまま、あるいは治療されないまま放置されると、血管や組織の詰まり、進行性の腎不全、神経障害、さらには脳卒中を引き起こす可能性があります。現在、ファブリー病は酵素補充療法（ERT）と補助療法によって治療することができます。これとは別に、腎臓や心臓の問題の発生を抑制するために、遺伝子検査、血液検査、非経口検査によってさらに診断することができます。これらのアプローチにより、第一および第二レベルの合併症の発症リスクを防ぎ、根本的な酵素欠乏症を改善することができます。その結果、病院や専門クリニックでは、ファブリー病のタイムリーな診断と効果的な治療のために様々な手技が広く活用されています。

ファブリー病市場の動向：

ファブリー病に罹患する患者数の増加と、罹患者を安定させるための遺伝子治療、酵素補充基質減少治療、シャペロン治療などの精密かつ効果的な治療に対するニーズの高まりが、主に市場成長の原動力となっています。これに伴い、疾患治療のための経口投与薬やカプセルの需要が高まっていることも、成長を促す要因となっています。さらに、画期的な疾患治療の選択肢を設計するためにヘルスケア部門に投資する規制機関によって行われている有利なイニシアチブが、市場の成長を支えています。さらに、ファブリー病の診断と治療のための遠隔医療ソリューションや在宅ケア環境の導入など、著しい技術進歩が市場成長を後押ししています。また、ファブリー病に関する意識の高まりも市場を大きく牽引しています。医師や個人の間で、早期診断や複数の予防策が利用可能であるという意識が高まっており、これが市場成長に寄与しています。あらゆる種類の慢性疾患にかかりやすい老年人口が着実に増加していることも、市場成長に寄与している要因です。その他の要因としては、ヘルスケアインフラの大幅な改善、遺伝性疾患治療の進歩に対する重点的な取り組み強化、治療・投薬ポートフォリオを拡充するための継続的な研究開発活動などが挙げられ、市場の明るい見通しを生み出しています。

本レポートで扱う主な質問

  • 世界のファブリー病市場はこれまでどのように推移し、今後数年間はどのように推移するのか？
  • 世界のファブリー病市場における市場促進要因、市場抑制要因、機会は何か？
  • 主要な地域市場は？
  • 最も魅力的なファブリー病市場はどの国か？
  • タイプ別の市場内訳は？
  • 診断と治療別市場内訳は？
  • エンドユーザー別の市場内訳は？
  • 世界のファブリー病市場の競争構造は？
  • 世界のファブリー病市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 ファブリー病の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：タイプ別

  • タイプ1
    • 市場動向
    • 市場予測
  • タイプ2
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：診断・治療別

  • 診断
    • 市場動向
    • 主要セグメント
      • 血液検査
      • 遺伝子検査
      • 非経口検査
      • その他
    • 市場予測
  • 治療
    • 市場動向
    • 主要セグメント
      • 酵素補充療法
      • 経口療法
      • 補助療法
      • その他
    • 市場予測

第8章 市場内訳：エンドユーザー別

  • 病院
    • 市場動向
    • 市場予測
  • 在宅医療
    • 市場動向
    • 市場予測
  • 専門クリニック
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 促進要因、抑制要因、機会

  • 市場概要
  • 促進要因
  • 抑制要因
  • 機会

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Amicus Therapeutics
    • Freeline
    • Idorsia Pharmaceuticals Ltd
    • JCR Pharmaceuticals Co. Ltd
    • Protalix BioTherapeutics
    • Sangamo Therapeutics Inc.
図表

List of Figures

  • Figure 1: Global: Fabry Disease Market: Major Drivers and Challenges
  • Figure 2: Global: Fabry Disease Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Fabry Disease Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Fabry Disease Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Fabry Disease Market: Breakup by Diagnosis & Treatment (in %), 2023
  • Figure 6: Global: Fabry Disease Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Fabry Disease Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Fabry Disease (Type 1) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Fabry Disease (Type 1) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Fabry Disease (Type 2) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Fabry Disease (Type 2) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Fabry Disease (Other Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Fabry Disease (Other Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Fabry Disease (Diagnosis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Fabry Disease (Diagnosis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Fabry Disease (Treatment) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Fabry Disease (Treatment) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Fabry Disease (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Fabry Disease (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Fabry Disease (Homecare) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Fabry Disease (Homecare) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Fabry Disease (Specialty Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Fabry Disease (Specialty Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Fabry Disease (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Fabry Disease (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: North America: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: North America: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: United States: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: United States: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Canada: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Canada: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Asia-Pacific: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Asia-Pacific: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: China: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: China: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Japan: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Japan: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: India: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: India: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: South Korea: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: South Korea: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Australia: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Australia: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Indonesia: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Indonesia: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Others: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Others: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Europe: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Europe: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Germany: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Germany: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: France: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: France: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: United Kingdom: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: United Kingdom: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Italy: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Italy: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Spain: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Spain: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Russia: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Russia: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Others: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Others: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Latin America: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Latin America: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Brazil: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Brazil: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Mexico: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Mexico: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Others: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Others: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Middle East and Africa: Fabry Disease Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Middle East and Africa: Fabry Disease Market: Breakup by Country (in %), 2023
  • Figure 74: Middle East and Africa: Fabry Disease Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Global: Fabry Disease Industry: Drivers, Restraints, and Opportunities
  • Figure 76: Global: Fabry Disease Industry: Value Chain Analysis
  • Figure 77: Global: Fabry Disease Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Fabry Disease Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Fabry Disease Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Fabry Disease Market Forecast: Breakup by Diagnosis & Treatment (in Million US$), 2024-2032
  • Table 4: Global: Fabry Disease Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Fabry Disease Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Fabry Disease Market: Competitive Structure
  • Table 7: Global: Fabry Disease Market: Key Players
目次
Product Code: SR112024A6668

The global fabry disease market size reached US$ 2.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.6 Billion by 2032, exhibiting a growth rate (CAGR) of 6.34% during 2024-2032. The increasing number of patients suffering from fabry disease and the escalating need for effective novel therapies, such as genetic and enzyme replacement therapy, represent some of the key factors driving the market.

Fabry disease, or alpha galactosidase-A deficiency, represents a severe x-linked lysosomal inherited disorder that is caused by the lack of enzymes that are required to metabolize various lipid storage and fat-like components, including oils, fatty acids, and waxes. If left undiagnosed or untreated, it might result in clogging of blood vessels and tissue, progressive kidney failures, nerve damage, and even strokes. Currently, fabry disease can be treated with the support of enzyme replacement therapies (ERT) and adjunct therapy. Apart from this, it can be further diagnosed through genetic, blood, and parenteral examinations to inhibit the occurrence of kidney and heart problems. These approaches prevent the risk of developing first and second-level complications and correct underlying enzyme deficiency. Consequently, hospitals and specialty clinics widely utilize various procedures for the timely diagnosis and effective treatment of the Fabry disease.

Fabry Disease Market Trends:

The increasing number of patients suffering from fabry disease and the escalating need for precise and effective therapies, such as genetic, enzyme replacement substrate reduction, and chaperone treatments to stabilize individuals from suffering disease, are primarily driving the market growth. In line with this, the rising demand for orally administered medications and capsule for disease treatment is acting as another growth-inducing factor. Additionally, the favorable initiatives being undertaken by regulatory bodies to invest in the healthcare sector for the designing of breakthrough disease treatment options are supporting the market growth. Moreover, significant technological advancements, such as the introduction of telemedicine solutions and home care settings for the diagnosis and treatment of Fabry disease, are favoring the market growth. The market is also significantly driven by the rising awareness regarding the disease. There is an increasing consciousness regarding the availability of early-stage diagnosis and multiple preventive measures amongst physicians and individuals, which is contributing to the market growth. The steadily increasing geriatric population, which is susceptible to any kind of chronic ailments, is another factor contributing to the market growth. Other factors, such as significant improvements in the healthcare infrastructure, an enhanced focus on the advancement of the genetic disease therapies, and continuous research and development (R&D) activities to expand treatment and medication portfolios, are creating a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global fabry disease market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on type, diagnosis and treatment, and end user.

Type Insights:

Type 1

Type 2

Others

The report has also provided a detailed breakup and analysis of the fabry disease market based on the type. This includes Type 1, Type 2 and others.

Diagnosis and Treatment Insights:

Diagnosis

Blood Test

Genetic Test

Parenteral Test

Others

Treatment

Enzyme Replacement Therapy

Oral Therapy

Adjunct Therapy

Others

A detailed breakup and analysis of the fabry disease market based on the diagnosis and treatment has also been provided in the report. This includes diagnosis (blood test, genetic test, parental test, and others) and treatment (enzyme replacement therapy, oral therapy, adjunct therapy, and others).

End User Insights:

Hospitals

Homecare

Specialty Clinics

Others

A detailed breakup and analysis of the fabry disease market based on the end user has also been provided in the report. This includes hospitals, homecare, specialty clinics and others. According to the report, specialty clinics accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for Fabry disease. Some of the factors driving the North America fabry disease market included the increasing prevalence of fabry disease and the ongoing approvals of advanced therapeutics by regional governments for the disorder treatment.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global fabry disease market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Amicus Therapeutics, Freeline, Idorsia Pharmaceuticals Ltd, JCR Pharmaceuticals Co. Ltd, Protalix BioTherapeutics, Sangamo Therapeutics Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global fabry disease market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global fabry disease market?
  • What are the key regional markets?
  • Which countries represent the most attractive fabry disease markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the diagnosis and treatment?
  • What is the breakup of the market based on the end user?
  • What is the competitive structure of the global fabry disease market?
  • Who are the key players/companies in the global fabry disease market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Fabry Disease Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Type 1
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Type 2
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Diagnosis & Treatment

  • 7.1 Diagnosis
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Blood Test
      • 7.1.2.2 Genetic Test
      • 7.1.2.3 Parenteral Test
      • 7.1.2.4 Others
    • 7.1.3 Market Forecast
  • 7.2 Treatment
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Enzyme Replacement Therapy
      • 7.2.2.2 Oral Therapy
      • 7.2.2.3 Adjunct Therapy
      • 7.2.2.4 Others
    • 7.2.3 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Homecare
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Specialty Clinics
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amicus Therapeutics
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Freeline
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Idorsia Pharmaceuticals Ltd
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
    • 14.3.4 JCR Pharmaceuticals Co. Ltd
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Protalix BioTherapeutics
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Sangamo Therapeutics Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.